The role of blood and blood products in acquisition of cytomegalovirus (CMV) infections following transfusion was reviewed in this study. CMV IgG prevalence was particularly high in Bangladesh. Thus 97% of the study groups were 
not yet been defined, but blood has been strongly implicated as a vehicle of CMV transmission. However, CMV infection in the transfused patient might also result from reactivation of latent endogenous infection or from exogenous nosocomial sources unrelated to blood products.
Introduction
Considerable circumstantial data strongly suggest that primary infection and reactivation or reinfection with CMV occur frequently after transfusion. Among blood transfusion recipients, a spectrum of responses to cytomegalovirus (CMV) infection has been observed. These include a serological response in the absence of symptoms, the posttransfusion mononucleosis syndrome 1 , polyneuritis 2 , hepatitis 3 , and pericarditis 4 . Whereas, in immunocompromised patients with malignant tumors, especially leukaemias and lymphomas, CMV is of major concern in causing tissue injury and death 5 . This also applies for organ transplant recipients and other immunosuppressed patients 6 . The pathogenesis and the epidemiology of these infections have
Statistical Analysis
The qualitative and numerical data obtained from the study were entered into SPSS-12.0 for windows and analyzed. Test of significance was estimated by Chi-square test. Probability less than 0.05 were considered as significant.
Results
Sero-status of IgG in multiple transfused patients (n=100), and apparently healthy control group (n=100) was shown in table:1. CMV IgG antibody was detected in all (100%) of the 100 multiple transfused patients and in 94% of the 100 apparently healthy persons. IgG response in multiple transfused patients and controls were comparable (P> 0.05).
CMV IgM antibody was detected in 24% of the 100 multiple transfused patients and 2 (2%) of the 100 apparently healthy persons (Table I) . CMV IgM antibody prevalence was significantly higher in multiple transfused groups ((P< 0.01) than control groups. 
Discussion
In the current study CMV IgG antibody was detected in 97% of the study groups including 100% of multiple transfused patients and even 94% of the apparently healthy controls were found to be CMV IgG antibody positive. The result reflect the fact that CMV IgG prevalence is high in Bangladesh. This high prevalence may be due to lower socioeconomic status, crowded, poor living standard, and child rearing practice in this community. The prevalence of antibody is also significantly higher in developing countries of Africa and Southeast Asia. Mathur et al 17 reported 83.5% It has been known for >20 years that CMV may be transmitted by blood 1 . Peripheral blood and bone marrow derived monocyte and granulocyte-macrophage progenitor cells (GM-PS) may be important sites of CMV latency 11 . Presumably, such cell must survive after transfusion and be activated to produce infection in the recipient. The uncertainty concerning how and under what circumstances this occurs may underlie some of the unexplained aspects of transfusion biology. Yeager et al 12 showed that ~14% of babies born of seronegative mothers became infected after they were transfused with seropositive blood. The infecting dose of blood was between 50 and 100 ml, a remarkably low figure when one considers that one unit of blood (500 ml). Approximately 45% of patients who yield negative results in tests for antibody to CMV and who undergo cardiopulmonary-bypass perfusion exhibit evidence of CMV infection after the operation 13 . On the basis of the observed incidence of post-transfusion CMV infection, the risk of contracting CMV has been estimated to be ~ 0.38% per unit of seropositive blood 14 . They observed that patients who received >30 units of cellular blood product had a significant higher risk of acquiring CMV infection. An excellent study by Palohcimo et al. 15 in 1968 suggested that these infections were primarily associated with transfusion of fresh blood . Another report suggested that only the total volume of blood mattered, not the age of transfused blood 16 . Thus, CMV infection may follow surgery and transfusion with fresh or old blood, though more risk is likely to incur with fresh blood.
Materials & Methods
100 Multiple transfused patients consisted of: a) 60 multiple transfused patients with Hereditary haemolytic anaemia and b) 40 patients with chronic renal failure (CRF) getting multiple transfusion and 100 control subjects were tested for IgG and IgM antibody for CMV by ELISA. Multiple transfused patients who were getting at least more than 50 units of blood transfusion and immunocompetent, non transfused controls with no history of fever and rashes within 2 months were included in the study. Samples of control group were collected from the doctors and staffs of BSMMU. 2-3 ml venous blood was collected to obtain serum for serology and were stored at -20 0 until the tests were performed . The samples were labeled and case number was recorded on the clinical data sheet immediately. patients the use of blood products from seronegative donors is both appropriate and likely to prevent posttransfusion CMV infection.
Transfusion-associated cytomegalovirus infection (TA-CMV)
is associated with considerable morbidity and mortality in atrisk populations, which include CMV-seronegative neonates, patients with AIDS, and stem cell transplant (SCT) recipients. The provision of CMV-seronegative blood product support to these individuals became the standard of care in the late 1980s after studies showed this strategy significantly reduced the rate of TA-CMV 12, 24, 25 . Donor population, however, vary considerably in their seropositivity rates, a situation thus limiting the available supply of seronegative bloods in some areas like Bangladesh. Thus, alternate methods for the provision of "CMV-safe" blood products have been pursued. Studies have demonstrated that CMV is latent in cells of the monocyte/macrophage lineage and that these cells can support CMV replication 26 . Third-generation filters effectively remove approximately 3-log 10 of the contaminating leukocytes in blood products 27 ,thus reducing the probability of TA-CMV. It is universally recognized that IgM antibody against a virus is indication of primary infection or reactivation of latent infection. Thus in this study 24% of 100 multiple transfused patients with CMV IgM antibody either had primary infection or reactivation of latent CMV infection. But 94% of IgG prevalence in healthy controls and 100% in multitransfused patients reflect that the IgM prevalence in this study was may be due to reactivation or reinfection of CMV infection. From the study it appeared that CMV reactivation or reinfection occurred at a higher rate in multi transfused patient due to allogeneic stimulation by transfusion or transfusion transmitted reinfection.
Henle et al 22 estimated that 5 to 12% of blood donors were carriers of the virus based on serological responses in recipients, and they also found, as confirmed by Prince et al 23 , a positive correlation between the volume of blood transfused and the risk of CMV seroconversion. CMV infection following transfusion is most likely secondary to reactivation of latent virus either in donor white blood cells or host tissues. Recent studies of neonatal CMV infections acquired following transfusion proved that blood donors with antibodies to CMV (seropositive) are the source of CMV infection for patients lacking antibodies to CMV (seronegative) 12 . Most CMV infections acquired after transfusion are either asymptomatic or characterized by a self-limited infectious mononucleosis syndrome. There are, however, specific groups of patients for whom a primary CMV infection after transfusion may cause significant morbidity and/or mortality. The patients at risk are seronegative and include pregnant women, premature infants, recipients of organ transplants from seronegative donors, and limited groups of severely immunosuppressed oncology patients. Current data suggest that for these seronegative
